Agricultural biologicals: which startup is ahead?
In our regenerative agriculture market deck, you will find everything you need to understand the market
SUMMARY
Groundwork BioAg is ahead in agricultural biologicals today, with Pivot Bio close behind and still capable of taking first place.
Groundwork has the strongest current commercial case: Rootella reached a reported 5.5 million acres across 23 markets in 2025, while the company has raised less than $30 million. No other startup combines that footprint, geographic reach, and capital efficiency.
Pivot has built the stronger scientific and technical foundation. Its gene-edited nitrogen-fixing microbes address a huge fertilizer market, peer-reviewed research supports the mechanism, and years of field experience have created a moat that would be difficult to reproduce.
The 2022 season is the reason Pivot does not lead. It reached more than three million acres and over $60 million in revenue, but too many growers received inconsistent results. The relaunch looks credible; the next harvest and repeat-purchase data will decide whether the comeback is real.
The acreage comparison is useful, but not perfectly clean. Groundwork’s 5.5 million acres come from one recent year, Pivot’s best completed season dates from 2022, Sound’s two million acres appear cumulative, and Puna’s 800,000 acres span three commercial seasons.
Puna Bio is the fastest grower relative to its size. Reaching more than 800,000 acres with roughly $24 million of funding is exceptional, and successful expansion beyond South America could move it into the top three.
Funding has been a poor guide to leadership. Indigo Ag and Pivot account for close to two-thirds of the roughly $3.2 billion raised by the 12 companies, yet Indigo discloses far less product-level adoption than much smaller Groundwork, Puna, or Sound.
Carbon-linked products are creating a second route to farmer value. Groundwork has issued independently verified credits, while Loam has published a striking Australian farm return, although the result cannot be credited to the biological product alone because the farm also changed other practices.
Several narrower companies already lead their own niches. GreenLight is ahead in RNA crop protection, NewLeaf in commercial PPFM products, Loam in fungal soil carbon, and AgroSpheres in encapsulated biofungicides.
The broad ranking is more trustworthy than the exact gaps. The missing numbers are still annual product revenue, gross margin, repeat orders, retention, and year-by-year acreage. Groundwork can secure the lead with another strong year and better independent agronomic evidence; Pivot can take it with a reliable harvest, higher repeat use, and a return above its previous acreage peak.
This market map, featured in our regenerative agriculture market deck, highlights top companies and startups in the regenerative agriculture market
Which agricultural biological startups belong in this race?
We found 12 independent startups with products that are already commercial or close enough to launch that farmers could realistically use them soon.
The comparison covers biofertilizers, biostimulants, biological crop protection, microbial seed treatments, and biological products tied to soil carbon. We also include Sound Agriculture because SOURCE activates microbes already living in the soil, even though the product itself is not a live microorganism.
We leave out Bayer, BASF, Syngenta, Corteva, UPL, Koppert, and other established agricultural-input groups. They compete with these startups, but including them would turn the article into a comparison between startups and global incumbents.
Vestaron is also excluded. Suterra recently acquired its products, active ingredients, research pipeline, and key R&D assets, so its peptide insecticides are no longer controlled by an independent startup.
Funding figures need some caution. Private-market databases do not always count grants, debt, strategic investments, and old financing rounds in the same way. The figures below are reasonable cumulative estimates rather than audited totals.
Together, these 12 companies have raised roughly $3.2 billion. Indigo Ag and Pivot Bio account for close to two-thirds of it, which already shows why funding alone gives a distorted picture of who is ahead.
| Startup | What it does | Approximate funding raised |
|---|---|---|
| Indigo Ag | Microbial seed and foliar products, alongside carbon and sustainability programs | $1.4B |
| Pivot Bio | Gene-edited microbes that supply nitrogen to corn and other crops | $618M |
| GreenLight Biosciences | RNA-based crop protection, led by its Calantha insecticide | $225M |
| Sound Agriculture | Products that activate the soil microbiome and improve nutrient availability | $195M |
| NewLeaf Symbiotics | PPFM microbes for crop growth, nutrition, insect control, and disease protection | $181M |
| Loam Bio | Fungal seed treatments connected to soil-carbon projects | $120M |
| Aphea.Bio | Microbial biostimulants and biological crop-protection products | $109M |
| AgroSpheres | Encapsulation technology for biological fungicides and pesticides | About $98M |
| BioConsortia | Microbial nitrogen fixation, crop protection, and biological discovery | About $95M |
| Kula Bio | Microbial production of biological nitrogen fertilizer | About $87M |
| Groundwork BioAg | Concentrated mycorrhizal inoculants and biological carbon removal | About $29M |
| Puna Bio | Seed treatments developed from microorganisms found in extreme environments | About $24M |
Is any agricultural biological startup clearly ahead today?
Yes, but only narrowly: Groundwork BioAg leads today, while Pivot Bio remains close enough to take first place.
Groundwork reported that Rootella was used across 5.5 million acres in 23 commercial markets during 2025. That is the largest recent acreage figure disclosed by an independent startup in this comparison.
Pivot Bio previously crossed three million acres in one season. Sound Agriculture says its products have reached around two million U.S. acres, while Puna Bio has passed 800,000 acres over its first three commercial seasons.
Those numbers point to a clear leading group, but they do not describe identical businesses. Groundwork sells mycorrhizal inoculants that can fit into many crops and planting systems. Pivot asks corn growers to reduce one of their most important inputs: synthetic nitrogen. GreenLight is introducing a new type of RNA insecticide. Loam combines a fungal seed treatment with carbon-credit generation.
Groundwork is ahead because it has the biggest recent commercial footprint, the widest geographic reach, and unusually strong capital efficiency. Pivot has better independent scientific evidence and a product that would have a much larger effect on fertilizer use if it worked reliably at scale.
If you want more recent data on this point, please see our latest regenerative agriculture market report.
As this chart shows, and as featured in our regenerative agriculture market deck, search interest in regenerative agriculture has been growing steadily
Which agricultural biological startups are already used at scale on real farms?
Groundwork BioAg has the strongest disclosed commercial scale, while eight startups have moved beyond trials into normal farm use.
Groundwork’s 5.5 million acres were reported for a single year. That puts the company about 83% above Pivot’s best completed season and well ahead of the totals disclosed by Sound and Puna.
The comparison becomes even more favorable to Groundwork once we look at the reporting periods. Pivot’s three-million-acre figure came from one season, but it dates from 2022. Sound’s two million acres appear to have accumulated over several years. Puna’s 800,000 acres cover three commercial seasons.
Groundwork has also moved beyond simply selling an inoculant. SCS Global independently verified the first 19,568 carbon units produced through its U.S. program under Verra’s standard. The company says it has already signed several agreements to sell those credits.
That gives Groundwork two commercial routes from the same product: farmers can buy Rootella for its agronomic effects, and some can also earn money from the additional carbon stored in their soil.
Indigo Ag shows why a distribution agreement cannot be treated as sales. Its multi-year partnership with GROWMARK gives Indigo access to a large network of FS cooperatives in the United States and Canada. Yet Indigo has not revealed how many acres, farmers, or repeat orders its biological products have generated through that channel.
Groundwork, Pivot, Sound, Puna, NewLeaf, Indigo, Loam, and GreenLight have all moved beyond laboratory research and small demonstration trials. Their levels of adoption vary widely, but farmers can buy and use their products today.
BioConsortia, AgroSpheres, Aphea.Bio, and Kula Bio are closer to the beginning of commercialization. They have credible products, investors, approvals, or distribution partners, yet none has disclosed adoption on the same scale as the leaders.
| Startup | Main commercial product | Where it stands now |
|---|---|---|
| Groundwork BioAg | Rootella and Rootella Carbon | Used at multi-million-acre scale across many international markets |
| Pivot Bio | PROVEN microbial nitrogen products | Commercial at scale, with a major relaunch under way after the 2022 problems |
| Sound Agriculture | SOURCE and BLUEPRINT | Established commercial products used across a large U.S. acreage base |
| Puna Bio | Kunza and Kanzama | Rapidly growing commercial adoption in South America |
| NewLeaf Symbiotics | Terrasym, TS201, TS601, and specialty-crop products | Several products already sold, with new crop and pest labels being added |
| Indigo Ag | Microbial seed and foliar treatments, including Nemora | Commercial portfolio with strong distribution but limited product-level disclosure |
| Loam Bio | CarbonBuilder and SecondCrop | Commercial in Australia and expanding into additional markets |
| GreenLight Biosciences | Calantha | Registered and sold in the U.S., with its first authorized European use |
| BioConsortia | Always-N | Early commercial rollout supported by Mosaic |
| AgroSpheres | FUN-THYME | First shipments completed and commercial manufacturing started |
| Aphea.Bio | ACTIV | One launched biostimulant, with the larger crop-protection pipeline still developing |
| Kula Bio | Microbial nitrogen platform | Commercial acceleration phase with little public adoption data |
Has Pivot Bio really recovered from its 2022 failure?
Pivot Bio looks much healthier now, but its comeback will only become fully convincing when harvest results confirm that the reliability problem has been fixed.
Pivot crossed three million acres and reported more than $60 million in revenue in 2022. That looked like a breakthrough until many growers received disappointing results.
The Wall Street Journal later reported that only slightly more than half of customers saw a yield benefit. Incorrect application, incompatible farm products, and excess nitrogen all contributed to the weak outcome.
Pivot did more than change its marketing after that failure. It replaced its chief executive, reformulated the product, strengthened its agronomy support, worked more closely with distributors, and lowered prices.
The promise has also become more realistic. Pivot used to be associated with replacing a large amount of synthetic fertilizer. These days, the company talks more often about supplying roughly 15% to 30% of a crop’s nitrogen, depending on field conditions.
Pivot now says more than 90% of growers benefit from its latest products. That figure comes from the company, so we should not treat it like an independent audit. Still, it would represent a major improvement from 2022.
The scientific case has strengthened as well. A three-year University of Illinois study published in Agronomy Journal found that Pivot’s gene-edited bacteria increased biological nitrogen fixation in corn. The research supports the mechanism behind the product, even though it cannot guarantee the same financial return on every farm.
Pivot’s N-OVATOR program is another useful sign. The company reported 1.4 million additional enrolled acres during 2024 and $4.5 million in farmer payments. It says those payments reduced the net product cost by about 30%.
If you want more recent data on this point, please see our latest regenerative agriculture market report.
This chart, featured in our regenerative agriculture market deck, illustrates yearly VC funding for regenerative agriculture startups
Which agricultural biological startup is growing fastest right now?
Puna Bio is growing fastest relative to its size, while Groundwork BioAg has the strongest overall momentum.
Puna reached more than 800,000 acres within three commercial seasons after raising only around $24 million. Its products began in Argentina, and the company is now expanding toward Brazil, the United States, Paraguay, and other agricultural markets.
The investors behind Puna also became more meaningful recently. Corteva Catalyst joined its latest financing, giving Puna a link to one of the world’s largest agricultural-input companies. The Gates Foundation also made its first investment in an Argentine startup through the round.
Groundwork is further ahead commercially. Its North American carbon program reportedly grew tenfold in one year, and it has now moved from enrolling farmers to producing independently verified credits and signing purchase agreements.
Those steps reinforce the same business. More product use can bring more farms into the carbon program, while successful credit sales give farmers another financial reason to use Rootella.
Pivot could be adding more acres than either company. Management says current demand should take it comfortably beyond its previous peak. Until the season is completed, however, that remains a forecast rather than a finished commercial result.
GreenLight recently secured the first authorized use of an RNA crop-protection product in the European Union. AgroSpheres opened its first commercial manufacturing facility. NewLeaf expanded its crop-protection labels and has said it wants to double sales. Loam is taking its Australian carbon model toward the United States and Brazil.
Which biological product has the strongest proof that it works?
Pivot Bio has the strongest overall evidence because its company trials are backed by peer-reviewed research and an unusually visible record of what went wrong before.
Most agricultural biological startups publish positive field results. Sound says SOURCE can replace 25 to 50 pounds of nitrogen per acre in suitable fields while maintaining or improving yield. Puna reports productivity improvements of around 10% to 15%. Groundwork and its partners have published corn and soybean yield increases ranging from roughly 5% to 15%.
We cannot place those percentages side by side as though they came from the same experiment. The trials cover different crops, soils, climates, fertilizer programs, controls, and weather conditions. The companies also choose which results to publish.
Pivot’s evidence is more useful because it includes both success and failure. The University of Illinois study supports the nitrogen-fixation mechanism. The weak 2022 customer results show that active microbes alone are not enough. Application, timing, compatibility, and the farmer’s wider nitrogen program can decide whether the product creates value.
GreenLight has strong proof in a narrower area. Calantha uses RNA interference to target Colorado potato beetle. Its registrations show that regulators accepted its mode of action, safety package, and proposed field use. Commercial evidence is still concentrated on one major pest in potatoes.
Groundwork’s large deployment offers another kind of proof. Farmers and distributors have continued to use Rootella across many markets, which would be difficult to sustain if the product had no perceived value. Independent, multi-location performance research remains thinner than Pivot’s.
If you want more recent data on this point, please see our latest regenerative agriculture market report.
This chart, featured in our regenerative agriculture market deck, shows why Agreena is winning in regenerative agriculture
Which startup saves farmers the most money?
Pivot Bio offers the clearest broadacre cost-saving case, while Loam Bio has produced the most striking return disclosed by a named individual farm.
Pivot says N-OVATOR payments reduce the farmer’s net product cost by around 30%, leaving its microbial nitrogen close to half the cost of an equivalent amount of synthetic nitrogen.
Sound says SOURCE can replace about 25 pounds each of nitrogen and phosphorus for roughly half the price of those conventional nutrients. The company has not disclosed how often farmers achieve the full saving or how many buy again.
Loam has published the strongest individual example. One Australian grower spent about A$40,000 applying CarbonBuilder across 880 hectares and later generated 4,867 Australian Carbon Credit Units valued at around A$200,000.
That represents roughly four to five times the initial spending before any yield improvement. The farm had also introduced several management changes, so the entire return cannot be attributed to CarbonBuilder alone.
Groundwork offers a similar carbon-linked model, with participating farmers able to receive up to 70% of net Rootella Carbon proceeds.
Who can actually deliver agricultural biologicals at scale?
Groundwork BioAg has built the strongest delivery network so far, while Pivot Bio faces the harder support challenge.
Groundwork operates in 23 commercial markets, including the United States, Brazil, India, and China. Concentrated formulations help its products move through existing storage, transport, and application systems.
BASF is a strategic investor, Beck’s connects U.S. growers to Rootella Carbon, and carbon buyers create another commercial route once credits are verified.
Pivot must manufacture effective microbes, keep them stable, prevent incompatibility with other inputs, and help farmers adjust nitrogen correctly. Its 2022 problems showed that shipping enough product was only part of the job.
Indigo has strong retail access through GROWMARK’s FS cooperative network, but it has not disclosed enough sales or repeat-purchase data to show that this access is producing scale.
AgroSpheres has opened a commercial manufacturing facility and launched FUN-THYME through Wilbur-Ellis. Its encapsulation process is designed to make biological active ingredients more stable and easier to store.
This chart, featured in our regenerative agriculture market deck, illustrates yearly funding for regenerative agriculture startups
Which agricultural biological startup would be hardest to copy?
Pivot Bio has the strongest all-round moat, while GreenLight Biosciences has built the hardest individual technology platform to reproduce.
Pivot combines gene-edited nitrogen-fixing microbes, patents, fermentation expertise, university research, field data, and practical knowledge gathered across millions of acres.
Another company could find a nitrogen-fixing organism. Reproducing Pivot’s field history, manufacturing knowledge, and agronomy system would take much longer.
GreenLight’s barrier comes from RNA crop protection. A competitor would need to manufacture double-stranded RNA economically, stabilize it for field use, complete safety studies, gain pesticide approvals, and persuade growers to adopt a new mode of action.
Its U.S. registration and first European authorization give it a meaningful head start.
Groundwork’s moat comes mainly from execution: strain selection, manufacturing, distribution, and carbon-credit infrastructure. Mycorrhizal inoculants are already a crowded category, making the underlying product easier to imitate.
NewLeaf has developed a distinct position around PPFM microbes, while Puna owns a growing library of microorganisms found in extreme environments. Loam combines fungal strains with carbon measurement and project development.
Has Indigo Ag turned $1.4 billion into a biologicals lead?
No. Indigo Ag has built a broad agricultural platform, but it has not shown enough biological-product traction to justify calling it the leader.
Indigo has raised more than twice as much capital as Pivot and close to 50 times as much as Groundwork. It has used that money across biologicals, digital grain trading, carbon markets, data products, and sustainability programs.
That broader strategy explains part of the spending. Even so, the biological side of the business remains unusually difficult to evaluate.
Indigo has commercial products and a valuable partnership with GROWMARK. What it does not provide is comparable product-level revenue, annual acreage, repeat-purchase data, or customer-retention figures.
Groundwork built the widest disclosed recent footprint after raising less than $30 million. Puna reached substantial commercial acreage with about $24 million. Those companies have produced much clearer adoption relative to the capital they consumed.
Pivot has also spent heavily, but the comparison is more forgiving. It developed gene-edited organisms, built fermentation capacity, conducted years of trials, created a farmer-support system, and attempted to replace part of a major commodity input.
Funding can still become an advantage for Indigo. Its retail network, brand, data, and carbon business could help it bundle biological products more effectively than smaller competitors.
That potential has not yet become visible market leadership. Today, Indigo is the best-funded company rather than the best-performing biologicals startup.
If you want more recent data on this point, please see our latest regenerative agriculture market report.
This chart, featured in our regenerative agriculture market deck, compares the main business model options for regenerative agriculture MRV and incentives platforms
Who leads each part of the agricultural biologicals market?
No startup leads every part of agricultural biologicals, although Groundwork and Pivot are the only two with a convincing claim to the overall number-one position.
The market covers products with very different jobs. Mycorrhizal fungi, microbial nitrogen, biostimulants, RNA pesticides, and carbon-linked seed treatments should not be judged by one identical metric.
GreenLight’s recent European authorization makes it the regulatory leader in RNA crop protection. NewLeaf has the widest commercial PPFM platform. Loam has the clearest early lead in fungal products designed specifically around soil-carbon generation.
| Market segment | Current leader | Why it leads |
|---|---|---|
| Mycorrhizal inoculants | Groundwork BioAg | Largest current commercial reach and a working carbon-credit extension |
| Gene-edited microbial nitrogen | Pivot Bio | Deepest field history, strongest independent research, and the clearest technical moat |
| Soil-microbiome activation | Sound Agriculture | Established commercial acreage and a simple nutrient-saving proposition |
| Extremophile biostimulants | Puna Bio | Fast adoption, low capital use, and early international expansion |
| PPFM crop health | NewLeaf Symbiotics | Commercial products across nutrition, insect control, and disease protection |
| Broad biological portfolio and retail access | Indigo Ag | Largest funding base and strongest named cooperative distribution channel |
| Fungal soil carbon | Loam Bio | First broadacre credits and a documented high-return farmer case |
| RNA crop protection | GreenLight Biosciences | First foliar RNA pesticide registration and first authorized EU use |
| Microbial discovery and licensing | BioConsortia | Strong discovery platform and Mosaic-supported nitrogen rollout |
| Encapsulated biofungicides | AgroSpheres | Commercial product, Wilbur-Ellis distribution, and dedicated manufacturing |
Can we trust the numbers agricultural biological startups publish?
We can trust the broad ranking more than the exact gaps.
The strongest evidence comes from regulatory documents, peer-reviewed studies, independently verified carbon credits, completed deployments, named distributors, and disclosed revenue.
Company-reported acreage, yield improvements, nutrient savings, and customer success rates are less reliable because companies rarely reveal failed trials, churn, discounts, or customers that do not reorder.
Biological products are also sensitive to soil, temperature, moisture, crop variety, storage, application timing, and compatibility with other inputs.
A recent survey of specialty-crop growers gave biologicals an average perception score of 6.85 out of 10. Farmers remained interested but wanted clearer financial returns and better advice.
One academic examination of a commercial biofertilizer also found that its reported yield improvements fell within the uncertainty of the data. It did not test the startups ranked here, but it shows why isolated trial percentages deserve caution.
The biggest missing figures are annual product revenue, gross margin, retention, repeat orders, and geographic sales. Indigo is especially opaque, while Sound gives little detail on how its acreage is divided by year.
Groundwork’s acreage and Pivot’s latest customer-success rate both come from the companies, although parts of Groundwork’s carbon program have been independently verified.
This chart, featured in our regenerative agriculture market deck, shows how market revenue is split across customer segments in the regenerative agriculture market
What could change the agricultural biologicals ranking?
A strong harvest could put Pivot Bio back in first place, while another year of commercial expansion could make Groundwork BioAg much harder to catch.
Pivot would probably move ahead if it surpassed its previous acreage peak, showed that most customers received a measurable benefit, and reported strong repeat purchases.
That would combine commercial scale with the best independent science and the strongest technical moat in the field.
Groundwork can make its lead more secure by maintaining its current adoption, issuing more verified carbon credits, disclosing product revenue, and producing stronger independent agronomic studies.
Its main vulnerability is product defensibility. Mycorrhizal inoculants are already offered by many established companies, which makes Groundwork’s commercial system more distinctive than the underlying category.
Sound could enter the top two by publishing annual acreage growth, repeat-purchase rates, and meaningful revenue figures. Its product is easier for farmers to understand than Pivot’s, but the public evidence is thinner.
Puna could rise quickly if its South American performance repeats in Brazil, the United States, Africa, or South Asia. Reaching two million acres while keeping its current capital efficiency would put it close to Sound.
NewLeaf needs sales data to support its expanding product range. Indigo needs to prove that GROWMARK is producing adoption rather than simple availability. GreenLight needs more commercial crops and permanent registrations. Loam needs to show that its first carbon success can be repeated across many farms.
Which agricultural biological startup is actually ahead?
Groundwork BioAg is ahead overall today, with Pivot Bio close behind and still capable of taking first place.
Groundwork’s strongest advantage is the combination of 5.5 million acres, 23 commercial markets, low historical funding, and a carbon program that has already produced independently verified credits.
No other independent startup currently matches that mix of adoption, geographic reach, recent execution, and capital efficiency.
Pivot is the closest challenger because its technology could reshape a much larger agricultural input market. It has the strongest independent science, the deepest microbial-nitrogen experience, and the most defensible technical platform.
Pivot has already shown that it can reach around three million acres and generate more than $60 million in annual revenue. Its position weakened because expansion came before the product and support system were reliable enough.
Sound ranks third. Its commercial footprint is meaningful and its nutrient-saving pitch is easy to understand, but the company discloses less about sales, retention, and independent performance.
Puna ranks fourth because it has grown remarkably quickly on very little capital. A successful international expansion could move it into the top three.
NewLeaf takes fifth place through a broadening commercial portfolio and a distinctive microbial platform. Indigo follows because its funding and distribution are impressive, while its biological-product results remain too vague.
GreenLight and Loam are narrower businesses today. GreenLight leads the RNA pesticide segment, and Loam has one of the most interesting carbon-linked models. Neither has yet reached enough farmers to win the whole category.
The final answer is a narrow Groundwork lead rather than an easy victory. Groundwork has done more in the market lately. Pivot has built the stronger scientific and technical foundation.
| Rank | Startup | Why it ranks here |
|---|---|---|
| 1 | Groundwork BioAg | Largest recent disclosed deployment, wide international reach, strong capital efficiency, and a verified carbon business |
| 2 | Pivot Bio | Best independent science and strongest technical moat, with a commercial recovery that still needs final confirmation |
| 3 | Sound Agriculture | Large commercial footprint and a clear nutrient-saving proposition, but limited financial and retention disclosure |
| 4 | Puna Bio | Exceptional early growth on little capital, with international expansion now beginning |
| 5 | NewLeaf Symbiotics | Distinctive microbial platform, several commercial products, and expanding crop-protection labels |
| 6 | Indigo Ag | Powerful funding and distribution, but too little evidence of biological-product adoption |
| 7 | Loam Bio | Strong early position in fungal soil carbon and one convincing documented farmer return |
| 8 | GreenLight Biosciences | Clear RNA crop-protection leader, still concentrated on a small number of commercial uses |
| 9 | BioConsortia | Promising nitrogen product and a valuable Mosaic relationship, with scaled adoption still ahead |
| 10 | AgroSpheres | Commercial biofungicide, major distribution partner, and manufacturing capacity, but still early |
| 11 | Aphea.Bio | Credible science and funding, although most of its valuable crop-protection pipeline remains pre-scale |
| 12 | Kula Bio | Interesting nitrogen technology with the least visible commercial adoption in the comparison |
If you want more recent data on this point, please see our latest regenerative agriculture market report.
This chart, featured in our regenerative agriculture market deck, shows how soil health monitoring technology has evolved over time
OUR METHODOLOGY
This analysis asks which independent agricultural biological startup is ahead today. We compare 12 companies across commercial scale, recent momentum, product evidence, farmer economics, delivery capacity, technical defensibility, and capital efficiency.
The comparison covers biofertilizers, biostimulants, biological crop protection, microbial seed treatments, and biological products tied to soil carbon. Sound Agriculture is included because SOURCE activates microbes already present in the soil. Established agricultural-input groups and acquired platforms are excluded so the ranking remains focused on independent startups.
We gave the most weight to completed execution. Recent farm deployments counted more than projected demand, measured adoption counted more than access to a distribution network, and commercial launches, regulatory decisions, disclosed revenue, peer-reviewed research, and independently verified outcomes strengthened company-reported claims.
Acreage figures were not treated as perfectly comparable. Some represent one completed season, some are cumulative, and some come from company disclosures without detailed year-by-year breakdowns. Older evidence remained relevant when it was still the clearest proof that a company had reached meaningful scale.
We did not compare yield, nutrient-replacement, or productivity percentages as though they came from equivalent trials. The products address different crops, pests, soils, climates, application systems, and farm economics. We judged the independence, breadth, and commercial relevance of the supporting evidence within each product’s use case.
Funding figures are approximate cumulative estimates because databases differ in how they count grants, debt, strategic investments, and older rounds. Funding was used as context and as an input to capital-efficiency analysis, not as a direct measure of market leadership.
The final ranking combines the conclusions from each dimension. It distinguishes current leadership from future potential: a company can have stronger science, a larger addressable market, or a more defensible platform without having the strongest commercial position today.
Key sources include Groundwork BioAg on Rootella’s reported 5.5 million-acre deployment and 23-market reach, SCS Global Services on the independent verification of Groundwork’s soil-carbon credits, Pivot Bio’s 2022 impact report on acreage and revenue, Pivot Bio’s N-OVATOR results, and peer-reviewed research on Pivot Bio’s gene-edited nitrogen-fixing microbes.
We also used Sound Agriculture’s disclosed SOURCE acreage, Indigo Ag and GROWMARK’s distribution announcement, the U.S. Environmental Protection Agency’s registration of ledprona, GreenLight Biosciences on the first authorized European use of its RNA insecticide, and AgroSpheres and Wilbur-Ellis on the commercial launch of FUN-THYME.
In our regenerative agriculture market deck, we identify pain points entrepreneurs should prioritize
Related blog posts
- Precision fermentation: which startup is ahead?
